Nanobiotix (NBTX) Stock: Buy, Sell, or Hold?
NBTX - Nanobiotix S.A. American Depositary Shares
$37.01
-0.59 (-1.57%)
▼
5d:
-7.48%
30d:
-6.16%
90d:
+4.76%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 29, 2026
16d
Get Alerted When NBTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NBTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NBTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NBTX is currently trading at $37.01, which is considered oversold relative to its 30-day fair value range of $37.62 to $42.64. From a valuation perspective, the stock is trading at a discount (Forward PE: -126.2) compared to its historical average (178.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NBTX is showing sideways momentum. Immediate support is located at $35.45, while resistance sits at $45.02.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.28 (+22.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NBTX is showing sideways momentum. Immediate support is located at $35.45, while resistance sits at $45.02.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.28 (+22.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$37.62 -
$42.64
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.3% below Wall St target ($45.28)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$37.62 -
$42.64
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$35.45
Resistance Level
$45.03
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-126.23
Wall Street Target
$45.28
(+22.3%)
Revenue Growth (YoY)
186.8%
Profit Margin
-73.5%
PE vs Historical
-126.2 vs 178.3
CHEAP
Share & Embed Analysis
Last updated: September 12, 2026 3:41 PM ET
Data refreshes hourly during market hours. Next update: 4:41 PM
Data refreshes hourly during market hours. Next update: 4:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
